|
Mr. Bailey is Angiotech's Chief Financial Officer and is responsible for overseeing the Company's overall financial activities. In addition he manages Angiotech's corporate growth initiatives such as acquisitions corporate alliances and partnerships. Prior to joining Angiotech in 2003 he worked for over a decade as an investment banker most recently as leader of the biotechnology practice group at Credit Suisse First Boston and Donaldson Lufkin & Jenrette where he advised on over 50 completed transactions for biotechnology pharmaceutical and medical device companies including mergers acquisitions strategic alliances and a wide range of equity equity-linked and debt financings and worked with the firms' merchant banking and venture capital groups to identify and complete significant investments in life sciences companies.
Mr. Bailey received his A.B. in Economics from Harvard University in 1990 and his MBA from Harvard Business School in 1995. | 